Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Kyverna Therapeutics

Main focus: Next-generation cell therapies for autoimmune diseases

Company stage: Pre-clinical

Diseases (gene editing): Autoimmune diseases

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Emeryville, CA, USA



Gene editing partnerships: Intellia Therapeutics

Kyverna Therapeutics develops cellular therapies to treat autoimmune and inflammatory diseases. This includes both engineered regulatory T cells, CAR-T and SynNotch CAR-T cells. The company has licensed Intellia Therapeutics' CRISPR-Cas9 technology for the development of its allogeneic CD19-targeting CAR-T cell therapy.


HashtagKyverna Therapeutics

Company: Kyverna Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine